domingo, 21 de dezembro de 2014
sexta-feira, 19 de dezembro de 2014
You Can Do This Project
You Can Do This Project
'You are not alone.
We are a grassroots video movement by and for people with diabetes: validation and encouragement through honest talk. Share your diabetes story, and be a light in someone’s darkness.'
We are a grassroots video movement by and for people with diabetes: validation and encouragement through honest talk. Share your diabetes story, and be a light in someone’s darkness.'
segunda-feira, 15 de dezembro de 2014
sábado, 1 de novembro de 2014
sexta-feira, 31 de outubro de 2014
JDRF-Funded Islet Encapsulation Program Reaches Historic Milestone | JDRF: Improving Lives. Curing Type 1 Diabetes
JDRF-Funded Islet Encapsulation Program Reaches Historic Milestone | JDRF: Improving Lives. Curing Type 1 Diabetes
'New York, NY, October 29, 2014 — JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, announced today that JDRF-funded partner, ViaCyte, Inc., a leading regenerative medicine company, has for the first time ever implanted a person with type 1 diabetes (T1D) with an experimental encapsulated cell therapy product candidate, called VC-01TM, which is being developed for the treatment of T1D. This individual, and others to follow, is participating in a trial to evaluate the safety and efficacy of the VC-01 product candidate, a potential replacement source of insulin-producing cells.'
'New York, NY, October 29, 2014 — JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, announced today that JDRF-funded partner, ViaCyte, Inc., a leading regenerative medicine company, has for the first time ever implanted a person with type 1 diabetes (T1D) with an experimental encapsulated cell therapy product candidate, called VC-01TM, which is being developed for the treatment of T1D. This individual, and others to follow, is participating in a trial to evaluate the safety and efficacy of the VC-01 product candidate, a potential replacement source of insulin-producing cells.'
terça-feira, 14 de outubro de 2014
Doenças autoimunes: molécula reverte progressão | ALERT® ONLINE - PT
Doenças autoimunes: molécula reverte progressão | ALERT® ONLINE - PT
'Investigadores descobriram que uma molécula presente em todas as células vivas pode ajudar a combater as doenças autoimunes, para as quais ainda não existe atualmente cura, defende um estudo publicado na revista “Nature Communications”.
A principal função do sistema imunitário é a proteção contra doenças e infeções. No entanto, por razões desconhecidas, o sistema imune por vezes ataca as células, tecidos e órgãos saudáveis. Este processo resulta muitas vezes em doenças, como esclerose múltipla, diabetes tipo 1, lúpus ou artrite reumatoide.
Os investigadores do Brigham and Women's Hospital, nos EUA, descobriram recentemente que a molécula NAD+ pode proteger contra as doenças autoimunes através da alteração da resposta imune e transformação das células destrutivas em células protetoras. A molécula é também capaz de reverter a progressão da doença ao restaurar os danos nos tecidos causados pelo processo autoimune.
Para o estudo, os investigadores, liderados por Stefan G. Tullius, utilizaram um modelo experimental da encefalomielite, um modelo pré-clínico da esclerose múltipla humana. Constataram que a NAD+ bloqueava a inflamação, crónica ou aguda, ao regular a forma como um tipo de células imunes, os linfócitos T CD4+, se diferenciam.
O estudo apurou que os ratinhos que receberam linfócitos T CD4+ na presença da NAD+ apresentaram um atraso significativo no início da doença, assim como uma forma menos severa, o que demonstra que a molécula tem propriedades protetoras.
Os investigadores verificaram ainda que a molécula era capaz de restaurar a integridade dos tecidos, o que pode beneficiar os pacientes com danos avançados nos tecidos, causados pelas doenças autoimunes.
“Esta é uma molécula universal que pode potencialmente tratar não apenas as doenças autoimunes, mas também outras condições crónicas ou agudas, como a alergia, doença pulmonar obstrutiva crónica, sepsis e imunodeficiência”, revelou, em comunicado de imprensa, Stefan G. Tullius.'
ALERT Life Sciences Computing, S.A.
sábado, 9 de agosto de 2014
JDRF: Encapsulation
NewsFlash: Band-Aid Sized Encapsulation Device Goes to FDA!
VC-01™ Combination Product – Improving Diabetes Treatment
ViaCyte has integrated two of its novel technologies, PEC-01™ cells and the Encaptra® drug delivery system, into one therapy called VC-01™ combination product.
The goal is to begin testing in patients with type 1 diabetes within the next two years.
The goal is to begin testing in patients with type 1 diabetes within the next two years.
segunda-feira, 23 de junho de 2014
terça-feira, 10 de junho de 2014
terça-feira, 13 de maio de 2014
NC State News :: NC State News and Information » Injectable Nano-Network Controls Blood Sugar in Diabetics for Days at a Time
NC State News :: NC State News and Information » Injectable Nano-Network Controls Blood Sugar in Diabetics for Days at a Time
In a promising development for diabetes treatment, researchers have developed a network of nanoscale particles that can be injected into the body and release insulin when blood-sugar levels rise, maintaining normal blood sugar levels for more than a week in animal-based laboratory tests. The work was done by researchers at North Carolina State University, the University of North Carolina at Chapel Hill, the Massachusetts Institute of Technology and Children’s Hospital Boston.
“We’ve created a ‘smart’ system that is injected into the body and responds to changes in blood sugar by releasing insulin, effectively controlling blood-sugar levels,” says Dr. Zhen Gu, lead author of a paper describing the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. “We’ve tested the technology in mice, and one injection was able to maintain blood sugar levels in the normal range for up to 10 days.”
(...)
The new, injectable nano-network is composed of a mixture containing nanoparticles with a solid core of insulin, modified dextran and glucose oxidase enzymes. When the enzymes are exposed to high glucose levels they effectively convert glucose into gluconic acid, which breaks down the modified dextran and releases the insulin. The insulin then brings the glucose levels under control. The gluconic acid and dextran are fully biocompatible and dissolve in the body.
(...)
“This technology effectively creates a ‘closed-loop’ system that mimics the activity of the pancreas in a healthy person, releasing insulin in response to glucose level changes,” Gu says. “This has the potential to improve the health and quality of life of diabetes patients.”
Gu’s research team is currently in discussions to move the technology into clinical trials for use in humans.
In a promising development for diabetes treatment, researchers have developed a network of nanoscale particles that can be injected into the body and release insulin when blood-sugar levels rise, maintaining normal blood sugar levels for more than a week in animal-based laboratory tests. The work was done by researchers at North Carolina State University, the University of North Carolina at Chapel Hill, the Massachusetts Institute of Technology and Children’s Hospital Boston.
“We’ve created a ‘smart’ system that is injected into the body and responds to changes in blood sugar by releasing insulin, effectively controlling blood-sugar levels,” says Dr. Zhen Gu, lead author of a paper describing the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. “We’ve tested the technology in mice, and one injection was able to maintain blood sugar levels in the normal range for up to 10 days.”
(...)
The new, injectable nano-network is composed of a mixture containing nanoparticles with a solid core of insulin, modified dextran and glucose oxidase enzymes. When the enzymes are exposed to high glucose levels they effectively convert glucose into gluconic acid, which breaks down the modified dextran and releases the insulin. The insulin then brings the glucose levels under control. The gluconic acid and dextran are fully biocompatible and dissolve in the body.
(...)
“This technology effectively creates a ‘closed-loop’ system that mimics the activity of the pancreas in a healthy person, releasing insulin in response to glucose level changes,” Gu says. “This has the potential to improve the health and quality of life of diabetes patients.”
Gu’s research team is currently in discussions to move the technology into clinical trials for use in humans.
sexta-feira, 14 de março de 2014
A Look at Commercial Practical Cure Prospects - JDCA
'This report will profile 13 small to mid-size corporations—both public and private—that are conducting work that could directly or indirectly support a Practical Cure by 2025.
Eleven companies are based in the U.S. while the other two are in Israel and Canada. We have organized detailed summaries on each company’s research platform, and more critically, stage of development and speed to market.'
Website: thejdca.org
Eleven companies are based in the U.S. while the other two are in Israel and Canada. We have organized detailed summaries on each company’s research platform, and more critically, stage of development and speed to market.'
Website: thejdca.org
terça-feira, 11 de março de 2014
Dispositivo não invasivo para diabéticos vence prémio | ALERT® ONLINE - PT
Dispositivo não invasivo para diabéticos vence prémio | ALERT® ONLINE - PT
O projeto GlucoWise, um dispositivo não invasivo que mede os níveis de glicose através de nanosensores, venceu a 4.ª edição do concurso internacional de empreendedorismo tecnológico promovido pelo ISCTE.
A notícia avançada pela agência Lusa refere que o concurso Building Global Innovators, ou BGI, que tem a colaboração do programa MIT Portugal e atribui anualmente até um milhão de euros a novos projetos, vai lançar a sua 5.ª edição no final de março.
A startup GlucoWise que conta com a participação de George Palikaras, Frederico Bastos e Quinton Fivelman recebeu 100 mil euros por ter descoberto uma forma de os diabéticos medirem o açúcar no sangue, através de pequenos sensores instalados na orelha, dispositivo que transmite os resultados para um smartphone ou tablet.
O responsável pela GlucoWise, Quinton Fivelman, de origem sul-africana explicou que procuram financiamento para produzir um protótipo mais pequeno e entrar no mercado, o que deverá acontecer "dentro de poucos anos".
O dispositivo GlucoWise é de pequenas dimensões, não invasivo, e mede os níveis de açúcar a partir de sensores que podem estar no lóbulo da orelha, na mão, entre os dedos polegar e indicador, ou no pé, disse o investigador Quinton Fivelman.
Ao vencer o concurso, os promotores da GlucoWise terão oportunidade de apresentar o seu produto a investidores no decorrer do e-Teams bootcamp III no MIT.
ALERT Life Sciences Computing, S.A.
terça-feira, 25 de fevereiro de 2014
Ben-Gurion University researcher may have a cure for Type 1 diabetes — JNS.org
Ben-Gurion University researcher may have a cure for Type 1 diabetes — JNS.org
(...)
In 2003, Lewis began his research into the role of inflammation in injured islets, tiny clusters of insulin-producing cells scattered throughout the pancreas. And during that time he discovered that Alpha 1 Antitrypsin (AAT), an anti-inflammatory drug based on a natural protein our bodies produce each day and generally used to treat emphysema, not only shows promise for reducing insulin dependence but in some cases can actually cure a person of Type 1 diabetes.
(...)
The hormone insulin, produced by clusters of cells found on islets that reside in the pancreas, enables the body to remove glucose (sugar) from the blood into storage locations such as liver and muscle. These cells are the targets of an autoimmune response in Type 1 diabetes. When the cells become inflamed and ultimately malfunction, insulin can no longer be produced. In a healthy individual, the body naturally produces systemic AAT in the liver that helps repair tissue and reduces inflammation. It was recently established that AAT, although present in patients with Type 1 diabetes, does not function in its glycated form.
(...)
In three recent clinical trials that took place at BGU, the Barbara Davis Center for Childhood Diabetes at the University of Colorado School of Medicine, and the Joslin Diabetes Center (affiliated with Harvard Medical School), recently diagnosed patients received injections of functioning AAT in the form of a liquid slow-drip infusion. They basically regained the ability to fight inflammation and protect damaged cells from aberrant immune responses. Within eight to 12 weeks AAT therapy was withdrawn, and in several patients proper glucose levels were controlled without the need for insulin injections for more than two years.
(...)
The treatment, however, may not be effective for all patients. (...) Lewis said in all trials, if one has been diagnosed with Type 1 for more than six months “the benefits are minimal.”
(...)
In 2003, Lewis began his research into the role of inflammation in injured islets, tiny clusters of insulin-producing cells scattered throughout the pancreas. And during that time he discovered that Alpha 1 Antitrypsin (AAT), an anti-inflammatory drug based on a natural protein our bodies produce each day and generally used to treat emphysema, not only shows promise for reducing insulin dependence but in some cases can actually cure a person of Type 1 diabetes.
(...)
The hormone insulin, produced by clusters of cells found on islets that reside in the pancreas, enables the body to remove glucose (sugar) from the blood into storage locations such as liver and muscle. These cells are the targets of an autoimmune response in Type 1 diabetes. When the cells become inflamed and ultimately malfunction, insulin can no longer be produced. In a healthy individual, the body naturally produces systemic AAT in the liver that helps repair tissue and reduces inflammation. It was recently established that AAT, although present in patients with Type 1 diabetes, does not function in its glycated form.
(...)
In three recent clinical trials that took place at BGU, the Barbara Davis Center for Childhood Diabetes at the University of Colorado School of Medicine, and the Joslin Diabetes Center (affiliated with Harvard Medical School), recently diagnosed patients received injections of functioning AAT in the form of a liquid slow-drip infusion. They basically regained the ability to fight inflammation and protect damaged cells from aberrant immune responses. Within eight to 12 weeks AAT therapy was withdrawn, and in several patients proper glucose levels were controlled without the need for insulin injections for more than two years.
(...)
The treatment, however, may not be effective for all patients. (...) Lewis said in all trials, if one has been diagnosed with Type 1 for more than six months “the benefits are minimal.”
sexta-feira, 21 de fevereiro de 2014
sexta-feira, 17 de janeiro de 2014
Subscrever:
Mensagens (Atom)